1.29%
-5.29%
5.07%
-3.20%
76.66%
97.74%
137.05%
AI Spotlight on MEDCL
Company Description
MedinCell S.A. develops various therapeutic solutions.It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients.The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia.
Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain.The company is based in Jacou, France.
Market Data
| Last Price | 15.74 |
| Change Percentage | 1.29% |
| Open | 15.54 |
| Previous Close | 15.54 |
| Market Cap ( Millions) | 468 |
| Volume | 47109 |
| Year High | 19 |
| Year Low | 8.44 |
| M A 50 | 16.78 |
| M A 200 | 15.86 |
Financial Ratios
| FCF Yield | -2.96% |
| Dividend Yield | 0.00% |
| ROE | 75.22% |
| Debt / Equity | -144.43% |
| Net Debt / EBIDTA | -223.93% |
| Price To Book | -11.21 |
| Price Earnings Ratio | -18.28 |
| Price To FCF | -33.79 |
| Price To sales | 43.57 |
| EV / EBITDA | -28.79 |
News
- Jan -29 - Medincell: UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization
- Jan -29 - 3 Growth Companies With High Insider Ownership To Watch
- Jan -15 - Medincell: Publication of the 2025 Financial Calendar
- Dec -19 - Top Growth Companies With Strong Insider Ownership December 2024
- Dec -12 - Medincell to Join the Euronext SBF 120 Index
- Dec -10 - Medincell Publishes Its Consolidated Half-year Financial Results
- Dec -09 - Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement
- Nov -28 - Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 10th, 2024
- Nov -18 - MedinCell And 2 Other Top Growth Stocks With Strong Insider Ownership
- Nov -06 - Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3
- Nov -04 - Medincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241
- Nov -04 - Medincell’s partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241
- Oct -28 - Medincell Announces Participation in Leading Investor Conferences
- Oct -18 - 3 Euronext Paris Growth Stocks With Strong Insider Ownership
- Oct -18 - 3 Euronext Paris Growth Companies With Up To 15% Insider Ownership
- Oct -17 - 3 Growth Companies With High Insider Ownership On Euronext Paris
- Oct -17 - 3 Top Growth Companies With High Insider Ownership On Euronext Paris
- Oct -16 - Top Growth Companies With Insider Ownership On Euronext Paris October 2024
- Oct -16 - 3 High-Insider Growth Stocks To Watch On Euronext Paris
- Oct -15 - Discover Exclusive Networks And 2 More Leading Growth Stocks On Euronext Paris
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Products Received under Development Benefit
Expected Growth : 9.27 %
What the company do ?
Products Received under Development Benefit from MedinCell S.A. refers to the pipeline of products in development, benefiting from MedinCell's proprietary BEPO technology, which enables the controlled and sustained release of active pharmaceutical ingredients.
Why we expect these perspectives ?
MedinCell S.A.'s 9.27% growth in Products Received under Development Benefit is driven by increasing demand for innovative pharmaceutical products, strategic partnerships, and expansion into new markets. Additionally, advancements in drug delivery technologies and a strong pipeline of products in development contribute to this growth.
Segment n°2 -> Licenses, Milestones
Expected Growth : 9.33 %
What the company do ?
MedinCell S.A. has obtained licenses for its BEPO technology and achieved milestones in developing long-acting injectable formulations for various therapeutic areas.
Why we expect these perspectives ?
MedinCell S.A.'s 9.33% growth is driven by increasing demand for its innovative, long-acting injectable therapies, successful partnerships and collaborations, and strategic licensing agreements. Milestones achieved in clinical trials, regulatory approvals, and product launches also contribute to its growth. The company's strong pipeline and expanding portfolio of licensed products further support its upward trajectory.
Segment n°3 -> Royalties
Expected Growth : 8.9 %
What the company do ?
MedinCell S.A. pays royalties to its partners for the commercialization of its innovative, long-acting injectable therapies, sharing a percentage of product sales revenue.
Why we expect these perspectives ?
Strong demand for MedinCell's innovative drug delivery technologies, increasing partnerships with pharmaceutical companies, and successful product launches in new markets drive the 8.9% growth in royalties. Additionally, the expansion of MedinCell's intellectual property portfolio and rising sales of licensed products contribute to the growth.
Medincell S.A. Products
| Product Range | What is it ? |
|---|---|
| BEPO | A long-acting injectable formulation of risperidone for the treatment of schizophrenia |
| mdc-IRM | A long-acting injectable formulation of ivermectin for the prevention of river blindness |
| mdc-TTG | A long-acting injectable formulation of testosterone for the treatment of hypogonadism |
| mdc-COVID-19 | A long-acting injectable formulation of ivermectin for the treatment of COVID-19 |
MedinCell S.A.'s Porter Forces
Threat Of Substitutes
MedinCell S.A. operates in the pharmaceutical industry, where substitutes are available, but the company's innovative products and services reduce the threat of substitutes.
Bargaining Power Of Customers
MedinCell S.A. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products and services are specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
MedinCell S.A. relies on a few key suppliers for raw materials and services. While the company has some bargaining power due to its size and reputation, suppliers still have some negotiating power.
Threat Of New Entrants
The pharmaceutical industry has high barriers to entry, including significant regulatory hurdles and high research and development costs. This reduces the threat of new entrants for MedinCell S.A.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, with many established players and new entrants vying for market share. MedinCell S.A. faces intense competition from other companies with similar products and services.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 428.65% |
| Debt Cost | 7.62% |
| Equity Weight | -328.65% |
| Equity Cost | 9.15% |
| WACC | 2.58% |
| Leverage | -130.43% |
MedinCell S.A. : Quality Control
MedinCell S.A. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| GLPG.AS | Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that … |
| KURN.SW | Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. … |
| NANO.PA | Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles … |
| BIO3.DE | Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical … |
| BAVA.CO | Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
MedinCell
A-Score
1-Year Total Return ->
🥈
Kuros Biosciences
A-Score
1-Year Total Return ->
🥉
Galapagos
A-Score
1-Year Total Return ->
4
Bavarian Nordic
A-Score
1-Year Total Return ->
5
Biotest
A-Score
1-Year Total Return ->
6
